var data={"title":"Common terminology criteria for adverse events","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Common terminology criteria for adverse events</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/contributors\" class=\"contributor contributor_credentials\">Diane MF Savarese, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/contributors\" class=\"contributor contributor_credentials\">Reed E Drews, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/contributors\" class=\"contributor contributor_credentials\">Jennifer S Tirnauer, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 29, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1156990\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The National Cancer Institute (NCI) of the National Institutes of Health (NIH) has published standardized definitions for adverse events (AEs), known as the Common Terminology Criteria for Adverse Events (CTCAE, also called &quot;common toxicity criteria&quot; [CTC]), to describe the severity of organ toxicity for patients receiving cancer therapy. This topic presents selected tables describing some of the AEs graded in the most recent CTCAE (version 5.0), which was published in November 2017 and became effective in April 2018 [<a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/abstract/1\" class=\"abstract_t\">1</a>]; it also provides references for other adverse event reporting systems.</p><p>Additional information about specific chemotherapy- and radiation therapy-associated toxicity is presented in separate topic reviews, which are mentioned under the disease-specific headings included herein.</p><p>General effects of radiation therapy and molecularly-targeted agents (eg, vascular endothelial growth factor inhibitors, tyrosine kinase inhibitors) are also discussed in separate reviews. (See <a href=\"topic.htm?path=toxicity-of-molecularly-targeted-antiangiogenic-agents-non-cardiovascular-effects\" class=\"medical medical_review\">&quot;Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-prevention-and-treatment-of-radiation-induced-fibrosis\" class=\"medical medical_review\">&quot;Clinical manifestations, prevention, and treatment of radiation-induced fibrosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1938950925\"><span class=\"h1\">CTCAE OVERVIEW</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CTCAE stands for Common Terminology Criteria for Adverse Events; these criteria are also called &quot;common toxicity criteria.&quot; In CTCAE, an adverse event (AE) is defined as any abnormal clinical finding temporally associated with the use of a therapy for cancer; causality is not required. These criteria are used for the management of chemotherapy administration and dosing, and in clinical trials to provide standardization and consistency in the definition of treatment-related toxicity.</p><p>Several versions of the CTCAE have been published. There is no set schedule for publication; typically a version is available for several years and new updates are released to improve clarity, to reflect advances in scientific underpinnings, or, for version 4.0, to harmonize with the medical dictionary for regulatory activities (MeDRA) system organ class (SOC). Version 4.0 was published in 2009 and was replaced by version 5.0 (v5.0) in 2018. A comprehensive listing of the v5.0 CTCAE is available from the National Cancer Institute (NCI) on the <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm&amp;token=Qmx3K8wGQQekcPXJ5bTBpcn0FinUI8F2hO4xf09x3ej52IvR7kOqJoZmhB5fqFTirIqyzRZ8XoIJamOWMskP2j70/zo3pR2XSuWYQhzhZZI=&amp;TOPIC_ID=90856\" target=\"_blank\" class=\"external\">Cancer Therapy Evaluation Program (CTEP)</a> website.</p><p>Changes from version 4.0 to 5.0 include some differences in the grade for certain AEs (eg, cytokine release syndrome, hyperglycemia) <span class=\"nowrap\">and/or</span> in terminology (eg, the term &quot;prehypertension&quot; is no longer used). The major organ system categories are the same as in version 4.0, and many of the AE grades have not been changed.</p><p>In general, toxicity is graded as mild (Grade 1), moderate (Grade 2), severe (Grade 3), or life-threatening (Grade 4), with specific parameters according to the organ system involved. Death (Grade 5) is used for some of the criteria to denote a fatality occurring during treatment. Approximately 10 percent of the items in the NCI CTCAE represent symptoms, and these are reported by clinicians rather than patients. Versions of the CTCAE that rely on patient-reported outcomes are discussed below. (See <a href=\"#H898017791\" class=\"local\">'Other adverse event reporting systems'</a> below.)</p><p class=\"headingAnchor\" id=\"H2916119799\"><span class=\"h1\">CTCAE CATEGORIES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following represents a selection of some of the adverse events (AEs) graded in the most recent CTCAE (version 5.0 [v5.0]). A comprehensive listing of the v5.0 CTCAE is available from the National Cancer Institute (NCI) on the <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm&amp;token=Qmx3K8wGQQekcPXJ5bTBpcn0FinUI8F2hO4xf09x3ej52IvR7kOqJoZmhB5fqFTirIqyzRZ8XoIJamOWMskP2j70/zo3pR2XSuWYQhzhZZI=&amp;TOPIC_ID=90856\" target=\"_blank\" class=\"external\">Cancer Therapy Evaluation Program (CTEP)</a> website.</p><p class=\"headingAnchor\" id=\"H1156997\"><span class=\"h2\">Blood</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hematologic adverse event (AE) criteria include decreases in neutrophil, platelet, hemoglobin, and lymphocyte (including CD4 cell) counts (<a href=\"image.htm?imageKey=HEME%2F64984\" class=\"graphic graphic_table graphicRef64984 \">table 1</a>). In v5.0, most of these were moved to the &quot;Investigations&quot; category, which includes many types of laboratory values, imaging, and changes in measured parameters such as urine output or weight.</p><p>Hematologic consequences of cancer therapy are also discussed separately in UpToDate. (See <a href=\"topic.htm?path=hematologic-complications-of-malignancy-anemia-and-bleeding\" class=\"medical medical_review\">&quot;Hematologic complications of malignancy: Anemia and bleeding&quot;</a> and <a href=\"topic.htm?path=clinical-and-laboratory-aspects-of-platelet-transfusion-therapy\" class=\"medical medical_review\">&quot;Clinical and laboratory aspects of platelet transfusion therapy&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-neutropenic-fever-syndromes-in-adult-cancer-patients-at-low-risk-for-complications\" class=\"medical medical_review\">&quot;Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications&quot;</a> and <a href=\"topic.htm?path=treatment-of-neutropenic-fever-syndromes-in-adults-with-hematologic-malignancies-and-hematopoietic-cell-transplant-recipients-high-risk-patients\" class=\"medical medical_review\">&quot;Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)&quot;</a> and <a href=\"topic.htm?path=risk-assessment-of-adults-with-chemotherapy-induced-neutropenia\" class=\"medical medical_review\">&quot;Risk assessment of adults with chemotherapy-induced neutropenia&quot;</a> and <a href=\"topic.htm?path=use-of-granulocyte-colony-stimulating-factors-in-adult-patients-with-chemotherapy-induced-neutropenia-and-conditions-other-than-acute-leukemia-myelodysplastic-syndrome-and-hematopoietic-cell-transplantation\" class=\"medical medical_review\">&quot;Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation&quot;</a>.)</p><p>The grading scheme for febrile neutropenia remains in the section on blood and lymphatic system disorders. Febrile neutropenia only has definitions for Grades 3 through 5 toxicity (<a href=\"image.htm?imageKey=HEME%2F64984\" class=\"graphic graphic_table graphicRef64984 \">table 1</a>). However, all patients with fever in the setting of chemotherapy-induced neutropenia require immediate medical attention regardless of the toxicity grade, as discussed in detail separately. (See <a href=\"topic.htm?path=overview-of-neutropenic-fever-syndromes\" class=\"medical medical_review\">&quot;Overview of neutropenic fever syndromes&quot;</a> and <a href=\"topic.htm?path=fever-in-children-with-chemotherapy-induced-neutropenia\" class=\"medical medical_review\">&quot;Fever in children with chemotherapy-induced neutropenia&quot;</a> and <a href=\"topic.htm?path=diagnostic-approach-to-the-adult-cancer-patient-with-neutropenic-fever\" class=\"medical medical_review\">&quot;Diagnostic approach to the adult cancer patient with neutropenic fever&quot;</a>.)</p><p>Thromboembolic events are also graded:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Arterial thromboembolism (<a href=\"image.htm?imageKey=HEME%2F117315\" class=\"graphic graphic_table graphicRef117315 \">table 2</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Venous thromboembolism (<a href=\"image.htm?imageKey=ONC%2F87383\" class=\"graphic graphic_table graphicRef87383 \">table 3</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Superior vena cava syndrome (<a href=\"image.htm?imageKey=HEME%2F117316\" class=\"graphic graphic_table graphicRef117316 \">table 4</a>)</p><p/><p>Thrombotic microangiopathies (TMAs) are separated into thrombotic thrombocytopenic purpura (TTP) (<a href=\"image.htm?imageKey=HEME%2F117317\" class=\"graphic graphic_table graphicRef117317 \">table 5</a>) and hemolytic uremic syndrome (HUS) (<a href=\"image.htm?imageKey=HEME%2F117318\" class=\"graphic graphic_table graphicRef117318 \">table 6</a>). Separate discussions in UpToDate discuss differences among these and other TMAs. (See <a href=\"topic.htm?path=approach-to-the-patient-with-suspected-ttp-hus-or-other-thrombotic-microangiopathy-tma\" class=\"medical medical_review\">&quot;Approach to the patient with suspected TTP, HUS, or other thrombotic microangiopathy (TMA)&quot;</a> and <a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy\" class=\"medical medical_review\">&quot;Drug-induced thrombotic microangiopathy&quot;</a>.)</p><p>Prevention and treatment of thromboembolic disease in patients with cancer is discussed in separate topic reviews:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=risk-and-prevention-of-venous-thromboembolism-in-adults-with-cancer\" class=\"medical medical_review\">&quot;Risk and prevention of venous thromboembolism in adults with cancer&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=treatment-of-venous-thromboembolism-in-patients-with-malignancy\" class=\"medical medical_review\">&quot;Treatment of venous thromboembolism in patients with malignancy&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=thromboembolism-in-children-with-cancer\" class=\"medical medical_review\">&quot;Thromboembolism in children with cancer&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=thrombotic-complications-following-treatment-of-multiple-myeloma-with-immunomodulatory-drugs-thalidomide-lenalidomide-and-pomalidomide\" class=\"medical medical_review\">&quot;Thrombotic complications following treatment of multiple myeloma with immunomodulatory drugs (thalidomide, lenalidomide, and pomalidomide)&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1157011\"><span class=\"h2\">Cardiac</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cardiac adverse event (AE) criteria include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Heart failure (<a href=\"image.htm?imageKey=ONC%2F58345\" class=\"graphic graphic_table graphicRef58345 \">table 7</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Right ventricular dysfunction (<a href=\"image.htm?imageKey=ONC%2F99987\" class=\"graphic graphic_table graphicRef99987 \">table 8</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Left ventricular systolic dysfunction (<a href=\"image.htm?imageKey=ONC%2F99985\" class=\"graphic graphic_table graphicRef99985 \">table 9</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypotension (<a href=\"image.htm?imageKey=ONC%2F69770\" class=\"graphic graphic_table graphicRef69770 \">table 10</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypertension (<a href=\"image.htm?imageKey=ONC%2F87347\" class=\"graphic graphic_table graphicRef87347 \">table 11</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sinus bradycardia (<a href=\"image.htm?imageKey=HEME%2F91244\" class=\"graphic graphic_table graphicRef91244 \">table 12</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prolongation of the corrected QT interval (QTc) on the electrocardiogram (<a href=\"image.htm?imageKey=HEME%2F91251\" class=\"graphic graphic_table graphicRef91251 \">table 13</a>)</p><p/><p>Cardiac toxicities of radiation and specific chemotherapeutic drugs are discussed in the following UpToDate topic reviews:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=clinical-manifestations-monitoring-and-diagnosis-of-anthracycline-induced-cardiotoxicity\" class=\"medical medical_review\">&quot;Clinical manifestations, monitoring, and diagnosis of anthracycline-induced cardiotoxicity&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=prevention-and-management-of-anthracycline-cardiotoxicity\" class=\"medical medical_review\">&quot;Prevention and management of anthracycline cardiotoxicity&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=cardiotoxicity-of-nonanthracycline-cancer-chemotherapy-agents\" class=\"medical medical_review\">&quot;Cardiotoxicity of nonanthracycline cancer chemotherapy agents&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=cardiotoxicity-of-radiation-therapy-for-breast-cancer-and-other-malignancies\" class=\"medical medical_review\">&quot;Cardiotoxicity of radiation therapy for breast cancer and other malignancies&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=cardiotoxicity-of-trastuzumab-and-other-her2-targeted-agents\" class=\"medical medical_review\">&quot;Cardiotoxicity of trastuzumab and other HER2-targeted agents&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=toxicity-of-molecularly-targeted-antiangiogenic-agents-cardiovascular-effects\" class=\"medical medical_review\">&quot;Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1157667\"><span class=\"h2\">Fatigue</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Fatigue is graded according to its impact on activities of daily living (<a href=\"image.htm?imageKey=ONC%2F60072\" class=\"graphic graphic_table graphicRef60072 \">table 14</a>).</p><p>Performance status (PS) is not graded in the CTCAE. PS can be graded using the Karnofsky or the Eastern Cooperative Oncology Group (ECOG) scale (<a href=\"image.htm?imageKey=ONC%2F57945\" class=\"graphic graphic_table graphicRef57945 \">table 15</a>).</p><p class=\"headingAnchor\" id=\"H1157004\"><span class=\"h2\">Gastrointestinal</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gastrointestinal adverse event (AE) criteria include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Oral mucositis (<a href=\"image.htm?imageKey=ONC%2F60597\" class=\"graphic graphic_table graphicRef60597 \">table 16</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nausea and vomiting (<a href=\"image.htm?imageKey=ONC%2F69015\" class=\"graphic graphic_table graphicRef69015 \">table 17</a>); these are graded separately in CTCAE v5.0</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dysphagia (<a href=\"image.htm?imageKey=HEME%2F91245\" class=\"graphic graphic_table graphicRef91245 \">table 18</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Esophagitis (<a href=\"image.htm?imageKey=HEME%2F117322\" class=\"graphic graphic_table graphicRef117322 \">table 19</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Esophageal stenosis (<a href=\"image.htm?imageKey=GAST%2F93931\" class=\"graphic graphic_table graphicRef93931 \">table 20</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gastroparesis (<a href=\"image.htm?imageKey=HEME%2F91247\" class=\"graphic graphic_table graphicRef91247 \">table 21</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diarrhea (<a href=\"image.htm?imageKey=ONC%2F65649\" class=\"graphic graphic_table graphicRef65649 \">table 22</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Constipation (<a href=\"image.htm?imageKey=HEME%2F117320\" class=\"graphic graphic_table graphicRef117320 \">table 23</a>)</p><p/><p>Oral toxicity, treatment-related nausea and vomiting, gastroparesis, and enterotoxicity are also discussed in separate UpToDate topic reviews:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=oral-toxicity-associated-with-chemotherapy\" class=\"medical medical_review\">&quot;Oral toxicity associated with chemotherapy&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pathophysiology-and-prediction-of-chemotherapy-induced-nausea-and-vomiting\" class=\"medical medical_review\">&quot;Pathophysiology and prediction of chemotherapy-induced nausea and vomiting&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=radiotherapy-induced-nausea-and-vomiting-prophylaxis-and-treatment\" class=\"medical medical_review\">&quot;Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=malignancy-associated-gastroparesis-pathophysiology-and-management\" class=\"medical medical_review\">&quot;Malignancy-associated gastroparesis: Pathophysiology and management&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=enterotoxicity-of-chemotherapeutic-agents\" class=\"medical medical_review\">&quot;Enterotoxicity of chemotherapeutic agents&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=overview-of-gastrointestinal-toxicity-of-radiation-therapy\" class=\"medical medical_review\">&quot;Overview of gastrointestinal toxicity of radiation therapy&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1157045\"><span class=\"h2\">Hepatobiliary</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hepatobiliary toxicity includes hepatic failure, portal hypertension, and laboratory evidence of liver dysfunction (<a href=\"image.htm?imageKey=ONC%2F77533\" class=\"graphic graphic_table graphicRef77533 \">table 24</a>). In CTCAE v5.0, the laboratory findings of liver toxicity are graded separately under investigations. Portal hypertension and hepatic failure are classified under hepatobiliary disorders.</p><p>The term drug-induced liver injury (DILI), which is used to assign Grade 3 hepatic failure, is defined by Hy's law (ie, the drug causes hepatocellular injury, often transaminase elevations are much greater than three times the upper limit of normal, and no other reason can be found to explain the increased transaminases and total bilirubin) [<a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/abstract/2\" class=\"abstract_t\">2</a>]. Chemotherapy-induced hepatotoxicity and management of chemotherapy dosing in patients with underlying liver disease are discussed separately in UpToDate. (See <a href=\"topic.htm?path=chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease\" class=\"medical medical_review\">&quot;Chemotherapy hepatotoxicity and dose modification in patients with liver disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6532839\"><span class=\"h2\">Immune system and infusion reactions and extravasation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Complications of drug infusions include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infusion-related reactions (<a href=\"image.htm?imageKey=ONC%2F57843\" class=\"graphic graphic_table graphicRef57843 \">table 25</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Injection site reactions (<a href=\"image.htm?imageKey=ONC%2F114224\" class=\"graphic graphic_table graphicRef114224 \">table 26</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infusion site extravasation (<a href=\"image.htm?imageKey=HEME%2F91248\" class=\"graphic graphic_table graphicRef91248 \">table 27</a>)</p><p/><p>These are generally graded according to the degree of intervention needed.</p><p>Immune reactions include cytokine release syndrome (CRS) (<a href=\"image.htm?imageKey=HEME%2F114251\" class=\"graphic graphic_table graphicRef114251 \">table 28</a>), serum sickness (<a href=\"image.htm?imageKey=ONC%2F117356\" class=\"graphic graphic_table graphicRef117356 \">table 29</a>), and allergic and anaphylactic reactions (<a href=\"image.htm?imageKey=HEME%2F91249\" class=\"graphic graphic_table graphicRef91249 \">table 30</a>). If an allergic reaction is related to a drug infusion, the grading schema for infusion-related reactions should be used.</p><p>Management of these complications are discussed separately in UpToDate:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=infusion-reactions-to-systemic-chemotherapy\" class=\"medical medical_review\">&quot;Infusion reactions to systemic chemotherapy&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=infusion-related-reactions-to-therapeutic-monoclonal-antibodies-used-for-cancer-therapy\" class=\"medical medical_review\">&quot;Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=extravasation-injury-from-chemotherapy-and-other-non-antineoplastic-vesicants\" class=\"medical medical_review\">&quot;Extravasation injury from chemotherapy and other non-antineoplastic vesicants&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=overview-of-therapeutic-monoclonal-antibodies\" class=\"medical medical_review\">&quot;Overview of therapeutic monoclonal antibodies&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1157317\"><span class=\"h2\">Kidney and urinary tract</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acute kidney injury is graded clinically (ie, whether hospitalization or dialysis is indicated); increased creatinine is graded separately and classified under &quot;Investigations&quot; (<a href=\"image.htm?imageKey=HEME%2F91253\" class=\"graphic graphic_table graphicRef91253 \">table 31</a>).</p><p>Proteinuria (<a href=\"image.htm?imageKey=HEME%2F91255\" class=\"graphic graphic_table graphicRef91255 \">table 32</a>) and cystitis (<a href=\"image.htm?imageKey=HEME%2F91254\" class=\"graphic graphic_table graphicRef91254 \">table 33</a>) are also graded.</p><p>Chronic kidney disease is also graded; however, experts prefer to classify chronic kidney disease according to published guidelines from expert groups such as the Kidney Disease Outcomes Quality Initiative (KDOQI) and Kidney Disease Improving Global Outcomes (KDIGO) [<a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=definition-and-staging-of-chronic-kidney-disease-in-adults#H27258404\" class=\"medical medical_review\">&quot;Definition and staging of chronic kidney disease in adults&quot;, section on 'Definition and staging of chronic kidney disease'</a>.)</p><p>Further discussions of chemotherapy-induced nephrotoxicity and cystitis related to cancer therapy are presented separately. (See <a href=\"topic.htm?path=chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents\" class=\"medical medical_review\">&quot;Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents&quot;</a> and <a href=\"topic.htm?path=chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents\" class=\"medical medical_review\">&quot;Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Molecularly targeted agents&quot;</a> and <a href=\"topic.htm?path=cystitis-in-patients-with-cancer\" class=\"medical medical_review\">&quot;Cystitis in patients with cancer&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1157626\"><span class=\"h2\">Lung</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pulmonary adverse event (AE) criteria include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dyspnea (<a href=\"image.htm?imageKey=HEME%2F117321\" class=\"graphic graphic_table graphicRef117321 \">table 34</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pneumonitis (<a href=\"image.htm?imageKey=ONC%2F61493\" class=\"graphic graphic_table graphicRef61493 \">table 35</a>)</p><p/><p>Pulmonary toxicity of chemotherapeutic, molecularly targeted agents, and radiation-related lung injury are discussed in separate topic reviews:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pulmonary-toxicity-associated-with-antineoplastic-therapy-molecularly-targeted-agents\" class=\"medical medical_review\">&quot;Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=pulmonary-toxicity-associated-with-antineoplastic-therapy-cytotoxic-agents\" class=\"medical medical_review\">&quot;Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=radiation-induced-lung-injury\" class=\"medical medical_review\">&quot;Radiation-induced lung injury&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H3728182\"><span class=\"h2\">Metabolism and fluid balance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Electrolyte abnormalities related to cancer therapy include hyper- and hyponatremia, hyper- and hypokalemia, hyper- and hypocalcemia, hyper- and hypomagnesemia, hyperuricemia, and hypophosphatemia (<a href=\"image.htm?imageKey=HEME%2F91252\" class=\"graphic graphic_table graphicRef91252 \">table 36</a>). These are all graded separately under &quot;Investigations.&quot;</p><p>Hyperglycemia and hypoglycemia are also graded (<a href=\"image.htm?imageKey=HEME%2F91272\" class=\"graphic graphic_table graphicRef91272 \">table 37</a>), as is dehydration (<a href=\"image.htm?imageKey=HEME%2F111516\" class=\"graphic graphic_table graphicRef111516 \">table 38</a>).</p><p class=\"headingAnchor\" id=\"H1157725\"><span class=\"h2\">Neurologic and psychiatric</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neurologic disorders include paresthesias and motor and sensory neurotoxicity (<a href=\"image.htm?imageKey=ONC%2F78736\" class=\"graphic graphic_table graphicRef78736 \">table 39</a>).</p><p>Specific cranial neuropathies are graded (eg, oculomotor nerve (<a href=\"image.htm?imageKey=ONC%2F117357\" class=\"graphic graphic_table graphicRef117357 \">table 40</a>). Hearing impairment is graded separately (<a href=\"image.htm?imageKey=ONC%2F117341\" class=\"graphic graphic_table graphicRef117341 \">table 41</a>) and not considered to be an impairment of the vestibulocochlear nerve.</p><p>Agitation, confusion, and delirium are graded as psychiatric disorders (<a href=\"image.htm?imageKey=NEURO%2F91811\" class=\"graphic graphic_table graphicRef91811 \">table 42</a>).</p><p>Neurologic complications of chemotherapy and radiation therapy are also discussed separately in UpToDate:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=overview-of-neurologic-complications-of-platinum-based-chemotherapy\" class=\"medical medical_review\">&quot;Overview of neurologic complications of platinum-based chemotherapy&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=overview-of-neurologic-complications-of-non-platinum-cancer-chemotherapy\" class=\"medical medical_review\">&quot;Overview of neurologic complications of non-platinum cancer chemotherapy&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=acute-complications-of-cranial-irradiation\" class=\"medical medical_review\">&quot;Acute complications of cranial irradiation&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=complications-of-spinal-cord-irradiation\" class=\"medical medical_review\">&quot;Complications of spinal cord irradiation&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=brachial-plexus-syndromes#H21\" class=\"medical medical_review\">&quot;Brachial plexus syndromes&quot;, section on 'Neoplastic and radiation-induced brachial plexopathy'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=lumbosacral-plexus-syndromes#H16\" class=\"medical medical_review\">&quot;Lumbosacral plexus syndromes&quot;, section on 'Radiation plexopathy'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=prevention-and-treatment-of-chemotherapy-induced-peripheral-neuropathy\" class=\"medical medical_review\">&quot;Prevention and treatment of chemotherapy-induced peripheral neuropathy&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1157919\"><span class=\"h2\">Pain</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pain is graded by severity and effect on activities of daily living. Separate criteria are used to grade pain in different locations in the body; these should be consulted for specific grading of pain [<a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/abstract/1\" class=\"abstract_t\">1</a>]. The table (<a href=\"image.htm?imageKey=ONC%2F58287\" class=\"graphic graphic_table graphicRef58287 \">table 43</a>) summarizes some of the common features of pain grading.</p><p class=\"headingAnchor\" id=\"H1157064\"><span class=\"h2\">Skin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cutaneous complications include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alopecia (<a href=\"image.htm?imageKey=HEME%2F91256\" class=\"graphic graphic_table graphicRef91256 \">table 44</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acneiform rash (<a href=\"image.htm?imageKey=ONC%2F67786\" class=\"graphic graphic_table graphicRef67786 \">table 45</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hyperhidrosis (excessive sweating) (<a href=\"image.htm?imageKey=PALC%2F115344\" class=\"graphic graphic_table graphicRef115344 \">table 46</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Radiation dermatitis (<a href=\"image.htm?imageKey=HEME%2F91257\" class=\"graphic graphic_table graphicRef91257 \">table 47</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Palmar-plantar erythrodysesthesia syndrome (<a href=\"image.htm?imageKey=ONC%2F73474\" class=\"graphic graphic_table graphicRef73474 \">table 48</a>), which is also referred to as acral erythema or hand-foot syndrome. This table is also used for grading the severity of hand-foot skin reaction, which is seen with <a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">sorafenib</a>, <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a> and other agents targeting the vascular endothelial growth factor (VEGF) receptor, and has a different clinical and histologic appearance from the classic form of palmar-plantar erythrodysesthesia that is associated with conventional cytotoxic chemotherapy agents.</p><p/><p>Further discussions of chemotherapy-associated alopecia and cutaneous toxicity, as well as radiation-related dermatitis, are presented separately:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=chemotherapy-induced-alopecia\" class=\"medical medical_review\">&quot;Chemotherapy-induced alopecia&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=acute-complications-of-cranial-irradiation#H7\" class=\"medical medical_review\">&quot;Acute complications of cranial irradiation&quot;, section on 'Radiation dermatitis and alopecia'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=cutaneous-side-effects-of-conventional-chemotherapy-agents\" class=\"medical medical_review\">&quot;Cutaneous side effects of conventional chemotherapy agents&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=cutaneous-side-effects-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy\" class=\"medical medical_review\">&quot;Cutaneous side effects of molecularly targeted therapy and other biologic agents used for cancer therapy&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=radiation-dermatitis\" class=\"medical medical_review\">&quot;Radiation dermatitis&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H898017791\"><span class=\"h1\">OTHER ADVERSE EVENT REPORTING SYSTEMS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patient-Reported Outcomes (PRO) take into account the patient's perspective on adverse events (AEs), which may be under-detected using the existing CTCAE system [<a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/abstract/4\" class=\"abstract_t\">4</a>]. A PRO version of the National Cancer Institute (NCI) CTCAE (<a href=\"http://healthcaredelivery.cancer.gov/pro-ctcae/instrument.html&amp;token=Ovj02dre9LEwfCPMCmPplLS8IJPDBl7oNbXs3568rCr5q9bWoOcdZSXdOeUHikd3dd/HfnvKHrvgtgHh5UwW4K8AtSQsFLDSFqHlsS1NKKs=&amp;TOPIC_ID=90856\" target=\"_blank\" class=\"external\">PRO-CTCAE</a>) has been developed and validated but is not yet in widespread use [<a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/abstract/4-6\" class=\"abstract_t\">4-6</a>]. A systematic review of reports that compared CTCAE and PRO ratings using various PRO measures of AEs found fair to moderate agreement between the two systems, with large variations in many of the studies [<a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/abstract/7\" class=\"abstract_t\">7</a>]. Translations of this document are available in other languages including German, Spanish, and Danish [<a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/abstract/8-10\" class=\"abstract_t\">8-10</a>].</p><p>For some toxicities related to radiation therapy, alternative grading criteria are available from the <a href=\"http://www.rtog.org/ResearchAssociates/AdverseEventReporting.aspx&amp;token=Scq1N5L+DWgar/VarRidGl3DtUbGtGomMPAoDxt81rh2T3aLfs8TU1dzrJZDIQ1u9aBVyozZQgfjw6COYO7xfJFbvyEaDQwqzHZSqcaJW5A=&amp;TOPIC_ID=90856\" target=\"_blank\" class=\"external\">Radiation Therapy Oncology Group (RTOG).</a> However, the NCI CTCAE criteria are also relevant to grading the severity of radiation therapy-related toxicity. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-radiation-proctitis#H524509853\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and treatment of radiation proctitis&quot;, section on 'Management'</a>.)</p><p class=\"headingAnchor\" id=\"H1157547\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>This topic review presents tables of some of the toxicities graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 (v5.0), which was released in November 2017 and is effective as of April 1, 2018. (See <a href=\"#H1938950925\" class=\"local\">'CTCAE overview'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Selected tables for CTCAE categories are provided in the sections above (see <a href=\"#H2916119799\" class=\"local\">'CTCAE categories'</a> above). A comprehensive listing of the criteria is available from the NCI on the <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm&amp;token=Qmx3K8wGQQekcPXJ5bTBpcn0FinUI8F2hO4xf09x3ej52IvR7kOqJoZmhB5fqFTirIqyzRZ8XoIJamOWMskP2j70/zo3pR2XSuWYQhzhZZI=&amp;TOPIC_ID=90856\" target=\"_blank\" class=\"external\">Cancer Therapy Evaluation Program (CTEP)</a> website.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>References and links for other adverse event reporting systems such as the patient-reported outcomes (PRO-CTCAE) and criteria from the Radiation Therapy Oncology Group (RTOG) are listed above. (See <a href=\"#H898017791\" class=\"local\">'Other adverse event reporting systems'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed on March 09, 2018).</li><li class=\"breakAll\">https://www.fda.gov/downloads/Guidances/UCM174090.pdf (Accessed on March 28, 2018).</li><li><a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/abstract/3\" class=\"nounderline abstract_t\">Launay-Vacher V. Cancer and the kidney: individualizing dosage according to renal function. Ann Oncol 2013; 24:2713.</a></li><li><a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/abstract/4\" class=\"nounderline abstract_t\">Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014; 106.</a></li><li><a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/abstract/5\" class=\"nounderline abstract_t\">Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol 2015; 1:1051.</a></li><li><a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/abstract/6\" class=\"nounderline abstract_t\">Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Am Soc Clin Oncol Educ Book 2016; 35:67.</a></li><li><a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/abstract/7\" class=\"nounderline abstract_t\">Atkinson TM, Ryan SJ, Bennett AV, et al. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer 2016; 24:3669.</a></li><li><a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/abstract/8\" class=\"nounderline abstract_t\">Arnold B, Mitchell SA, Lent L, et al. Linguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Support Care Cancer 2016; 24:2843.</a></li><li><a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/abstract/9\" class=\"nounderline abstract_t\">B&aelig;ksted C, Nissen A, Pappot H, et al. Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Pain Symptom Manage 2016; 52:292.</a></li><li><a href=\"https://www.uptodate.com/contents/common-terminology-criteria-for-adverse-events/abstract/10\" class=\"nounderline abstract_t\">Hagelstein V, Ortland I, Wilmer A, et al. Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE&trade;). Ann Oncol 2016; 27:2294.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 90856 Version 22.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1157547\"><span>SUMMARY</span></a></li><li><a href=\"#H1156990\" id=\"outline-link-H1156990\">INTRODUCTION</a></li><li><a href=\"#H1938950925\" id=\"outline-link-H1938950925\">CTCAE OVERVIEW</a></li><li><a href=\"#H2916119799\" id=\"outline-link-H2916119799\">CTCAE CATEGORIES</a><ul><li><a href=\"#H1156997\" id=\"outline-link-H1156997\">Blood</a></li><li><a href=\"#H1157011\" id=\"outline-link-H1157011\">Cardiac</a></li><li><a href=\"#H1157667\" id=\"outline-link-H1157667\">Fatigue</a></li><li><a href=\"#H1157004\" id=\"outline-link-H1157004\">Gastrointestinal</a></li><li><a href=\"#H1157045\" id=\"outline-link-H1157045\">Hepatobiliary</a></li><li><a href=\"#H6532839\" id=\"outline-link-H6532839\">Immune system and infusion reactions and extravasation</a></li><li><a href=\"#H1157317\" id=\"outline-link-H1157317\">Kidney and urinary tract</a></li><li><a href=\"#H1157626\" id=\"outline-link-H1157626\">Lung</a></li><li><a href=\"#H3728182\" id=\"outline-link-H3728182\">Metabolism and fluid balance</a></li><li><a href=\"#H1157725\" id=\"outline-link-H1157725\">Neurologic and psychiatric</a></li><li><a href=\"#H1157919\" id=\"outline-link-H1157919\">Pain</a></li><li><a href=\"#H1157064\" id=\"outline-link-H1157064\">Skin</a></li></ul></li><li><a href=\"#H898017791\" id=\"outline-link-H898017791\">OTHER ADVERSE EVENT REPORTING SYSTEMS</a></li><li><a href=\"#H1157547\" id=\"outline-link-H1157547\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"HEME/90856|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/64984\" class=\"graphic graphic_table\">- NCI CTCAE v5 hematologic toxicity</a></li><li><a href=\"image.htm?imageKey=HEME/117315\" class=\"graphic graphic_table\">- NCI CTCAE v5 arterial thromboembolism</a></li><li><a href=\"image.htm?imageKey=ONC/87383\" class=\"graphic graphic_table\">- NCI CTCAE v5 thromboembolic event</a></li><li><a href=\"image.htm?imageKey=HEME/117316\" class=\"graphic graphic_table\">- NCI CTCAE v5 SVC syndrome</a></li><li><a href=\"image.htm?imageKey=HEME/117317\" class=\"graphic graphic_table\">- NCI CTCAE v5 thrombotic thrombocytopenic purpura</a></li><li><a href=\"image.htm?imageKey=HEME/117318\" class=\"graphic graphic_table\">- NCI CTCAE v5 hemolytic uremic syndrome</a></li><li><a href=\"image.htm?imageKey=ONC/58345\" class=\"graphic graphic_table\">- NCI CTCAE v5 heart failure</a></li><li><a href=\"image.htm?imageKey=ONC/99987\" class=\"graphic graphic_table\">- NCI CTCAE v5 right ventricular dysfunction</a></li><li><a href=\"image.htm?imageKey=ONC/99985\" class=\"graphic graphic_table\">- NCI CTCAE v5 left ventricular systolic dysfunction</a></li><li><a href=\"image.htm?imageKey=ONC/69770\" class=\"graphic graphic_table\">- NCI CTCAE v5 hypotension</a></li><li><a href=\"image.htm?imageKey=ONC/87347\" class=\"graphic graphic_table\">- NCI CTCAE v5 hypertension</a></li><li><a href=\"image.htm?imageKey=HEME/91244\" class=\"graphic graphic_table\">- NCI CTCAE v5 sinus bradycardia</a></li><li><a href=\"image.htm?imageKey=HEME/91251\" class=\"graphic graphic_table\">- NCI CTCAE v5 electrocardiogram QT corrected interval prolonged</a></li><li><a href=\"image.htm?imageKey=ONC/60072\" class=\"graphic graphic_table\">- NCI CTCAE v5 fatigue</a></li><li><a href=\"image.htm?imageKey=ONC/57945\" class=\"graphic graphic_table\">- Performance status measure</a></li><li><a href=\"image.htm?imageKey=ONC/60597\" class=\"graphic graphic_table\">- NCI CTCAE v5 mucositis oral</a></li><li><a href=\"image.htm?imageKey=ONC/69015\" class=\"graphic graphic_table\">- NCI CTCAE v5 nausea and vomiting</a></li><li><a href=\"image.htm?imageKey=HEME/91245\" class=\"graphic graphic_table\">- NCI CTCAE v5 dysphagia</a></li><li><a href=\"image.htm?imageKey=HEME/117322\" class=\"graphic graphic_table\">- NCI CTCAE v5 esophagitis</a></li><li><a href=\"image.htm?imageKey=GAST/93931\" class=\"graphic graphic_table\">- NCI CTCAE v5 esophageal stenosis</a></li><li><a href=\"image.htm?imageKey=HEME/91247\" class=\"graphic graphic_table\">- NCI CTCAE v5 gastroparesis</a></li><li><a href=\"image.htm?imageKey=ONC/65649\" class=\"graphic graphic_table\">- NCI CTCAE v5 diarrhea</a></li><li><a href=\"image.htm?imageKey=HEME/117320\" class=\"graphic graphic_table\">- NCI CTCAE v5 constipation</a></li><li><a href=\"image.htm?imageKey=ONC/77533\" class=\"graphic graphic_table\">- NCI CTCAE v5 hepatobiliary toxicity</a></li><li><a href=\"image.htm?imageKey=ONC/57843\" class=\"graphic graphic_table\">- NCI CTCAE v5 infusion-related reactions</a></li><li><a href=\"image.htm?imageKey=ONC/114224\" class=\"graphic graphic_table\">- NCI CTCAE v5 injection site reactions</a></li><li><a href=\"image.htm?imageKey=HEME/91248\" class=\"graphic graphic_table\">- NCI CTCAE v5 infusion site extravasation</a></li><li><a href=\"image.htm?imageKey=HEME/114251\" class=\"graphic graphic_table\">- NCI CTCAE v5 cytokine release syndrome</a></li><li><a href=\"image.htm?imageKey=ONC/117356\" class=\"graphic graphic_table\">- NCI CTCAE v5 serum sickness</a></li><li><a href=\"image.htm?imageKey=HEME/91249\" class=\"graphic graphic_table\">- NCI CTCAE v5 allergic reaction and anaphylaxis</a></li><li><a href=\"image.htm?imageKey=HEME/91253\" class=\"graphic graphic_table\">- NCI CTCAE v5 acute kidney injury, creatinine increased</a></li><li><a href=\"image.htm?imageKey=HEME/91255\" class=\"graphic graphic_table\">- NCI CTCAE v5 proteinuria</a></li><li><a href=\"image.htm?imageKey=HEME/91254\" class=\"graphic graphic_table\">- NCI CTCAE v5 cystitis noninfective</a></li><li><a href=\"image.htm?imageKey=HEME/117321\" class=\"graphic graphic_table\">- NCI CTCAE v5 dyspnea</a></li><li><a href=\"image.htm?imageKey=ONC/61493\" class=\"graphic graphic_table\">- NCI CTCAE v5 pneumonitis</a></li><li><a href=\"image.htm?imageKey=HEME/91252\" class=\"graphic graphic_table\">- NCI CTCAE v5 electrolyte abnormalities</a></li><li><a href=\"image.htm?imageKey=HEME/91272\" class=\"graphic graphic_table\">- NCI CTCAE v5 glucose abnormalities</a></li><li><a href=\"image.htm?imageKey=HEME/111516\" class=\"graphic graphic_table\">- NCI CTCAE v5 dehydration</a></li><li><a href=\"image.htm?imageKey=ONC/78736\" class=\"graphic graphic_table\">- NCI CTCAE v5 neurotoxicity</a></li><li><a href=\"image.htm?imageKey=ONC/117357\" class=\"graphic graphic_table\">- NCI CTCAE v5 oculomotor nerve disorder</a></li><li><a href=\"image.htm?imageKey=ONC/117341\" class=\"graphic graphic_table\">- NCI CTCAE v5 hearing impaired</a></li><li><a href=\"image.htm?imageKey=NEURO/91811\" class=\"graphic graphic_table\">- NCI CTCAE v5 agitation, confusion, delirium</a></li><li><a href=\"image.htm?imageKey=ONC/58287\" class=\"graphic graphic_table\">- NCI CTCAE v5 pain</a></li><li><a href=\"image.htm?imageKey=HEME/91256\" class=\"graphic graphic_table\">- NCI CTCAE v5 alopecia</a></li><li><a href=\"image.htm?imageKey=ONC/67786\" class=\"graphic graphic_table\">- NCI CTCAE v5 acneiform rash</a></li><li><a href=\"image.htm?imageKey=PALC/115344\" class=\"graphic graphic_table\">- NCI CTCAE v5 hyperhidrosis</a></li><li><a href=\"image.htm?imageKey=HEME/91257\" class=\"graphic graphic_table\">- NCI CTCAE v5 radiation dermatitis</a></li><li><a href=\"image.htm?imageKey=ONC/73474\" class=\"graphic graphic_table\">- NCI CTCAE v5 palmar-plantar erythrodysesthesia syndrome</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-complications-of-cranial-irradiation\" class=\"medical medical_review\">Acute complications of cranial irradiation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-suspected-ttp-hus-or-other-thrombotic-microangiopathy-tma\" class=\"medical medical_review\">Approach to the patient with suspected TTP, HUS, or other thrombotic microangiopathy (TMA)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=brachial-plexus-syndromes\" class=\"medical medical_review\">Brachial plexus syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cardiotoxicity-of-nonanthracycline-cancer-chemotherapy-agents\" class=\"medical medical_review\">Cardiotoxicity of nonanthracycline cancer chemotherapy agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cardiotoxicity-of-radiation-therapy-for-breast-cancer-and-other-malignancies\" class=\"medical medical_review\">Cardiotoxicity of radiation therapy for breast cancer and other malignancies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cardiotoxicity-of-trastuzumab-and-other-her2-targeted-agents\" class=\"medical medical_review\">Cardiotoxicity of trastuzumab and other HER2-targeted agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease\" class=\"medical medical_review\">Chemotherapy hepatotoxicity and dose modification in patients with liver disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-conventional-cytotoxic-agents\" class=\"medical medical_review\">Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chemotherapy-nephrotoxicity-and-dose-modification-in-patients-with-renal-insufficiency-molecularly-targeted-agents\" class=\"medical medical_review\">Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Molecularly targeted agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chemotherapy-induced-alopecia\" class=\"medical medical_review\">Chemotherapy-induced alopecia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-and-laboratory-aspects-of-platelet-transfusion-therapy\" class=\"medical medical_review\">Clinical and laboratory aspects of platelet transfusion therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-radiation-proctitis\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and treatment of radiation proctitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-monitoring-and-diagnosis-of-anthracycline-induced-cardiotoxicity\" class=\"medical medical_review\">Clinical manifestations, monitoring, and diagnosis of anthracycline-induced cardiotoxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-prevention-and-treatment-of-radiation-induced-fibrosis\" class=\"medical medical_review\">Clinical manifestations, prevention, and treatment of radiation-induced fibrosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=complications-of-spinal-cord-irradiation\" class=\"medical medical_review\">Complications of spinal cord irradiation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-side-effects-of-conventional-chemotherapy-agents\" class=\"medical medical_review\">Cutaneous side effects of conventional chemotherapy agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-side-effects-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy\" class=\"medical medical_review\">Cutaneous side effects of molecularly targeted therapy and other biologic agents used for cancer therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cystitis-in-patients-with-cancer\" class=\"medical medical_review\">Cystitis in patients with cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=definition-and-staging-of-chronic-kidney-disease-in-adults\" class=\"medical medical_review\">Definition and staging of chronic kidney disease in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-approach-to-the-adult-cancer-patient-with-neutropenic-fever\" class=\"medical medical_review\">Diagnostic approach to the adult cancer patient with neutropenic fever</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-induced-thrombotic-microangiopathy\" class=\"medical medical_review\">Drug-induced thrombotic microangiopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=enterotoxicity-of-chemotherapeutic-agents\" class=\"medical medical_review\">Enterotoxicity of chemotherapeutic agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=extravasation-injury-from-chemotherapy-and-other-non-antineoplastic-vesicants\" class=\"medical medical_review\">Extravasation injury from chemotherapy and other non-antineoplastic vesicants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fever-in-children-with-chemotherapy-induced-neutropenia\" class=\"medical medical_review\">Fever in children with chemotherapy-induced neutropenia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hematologic-complications-of-malignancy-anemia-and-bleeding\" class=\"medical medical_review\">Hematologic complications of malignancy: Anemia and bleeding</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infusion-reactions-to-systemic-chemotherapy\" class=\"medical medical_review\">Infusion reactions to systemic chemotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infusion-related-reactions-to-therapeutic-monoclonal-antibodies-used-for-cancer-therapy\" class=\"medical medical_review\">Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lumbosacral-plexus-syndromes\" class=\"medical medical_review\">Lumbosacral plexus syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=malignancy-associated-gastroparesis-pathophysiology-and-management\" class=\"medical medical_review\">Malignancy-associated gastroparesis: Pathophysiology and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=oral-toxicity-associated-with-chemotherapy\" class=\"medical medical_review\">Oral toxicity associated with chemotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-gastrointestinal-toxicity-of-radiation-therapy\" class=\"medical medical_review\">Overview of gastrointestinal toxicity of radiation therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-neurologic-complications-of-non-platinum-cancer-chemotherapy\" class=\"medical medical_review\">Overview of neurologic complications of non-platinum cancer chemotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-neurologic-complications-of-platinum-based-chemotherapy\" class=\"medical medical_review\">Overview of neurologic complications of platinum-based chemotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-neutropenic-fever-syndromes\" class=\"medical medical_review\">Overview of neutropenic fever syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-therapeutic-monoclonal-antibodies\" class=\"medical medical_review\">Overview of therapeutic monoclonal antibodies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-and-prediction-of-chemotherapy-induced-nausea-and-vomiting\" class=\"medical medical_review\">Pathophysiology and prediction of chemotherapy-induced nausea and vomiting</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-and-management-of-anthracycline-cardiotoxicity\" class=\"medical medical_review\">Prevention and management of anthracycline cardiotoxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-and-treatment-of-chemotherapy-induced-peripheral-neuropathy\" class=\"medical medical_review\">Prevention and treatment of chemotherapy-induced peripheral neuropathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-toxicity-associated-with-antineoplastic-therapy-cytotoxic-agents\" class=\"medical medical_review\">Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-toxicity-associated-with-antineoplastic-therapy-molecularly-targeted-agents\" class=\"medical medical_review\">Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=radiation-dermatitis\" class=\"medical medical_review\">Radiation dermatitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=radiation-induced-lung-injury\" class=\"medical medical_review\">Radiation-induced lung injury</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=radiotherapy-induced-nausea-and-vomiting-prophylaxis-and-treatment\" class=\"medical medical_review\">Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=risk-and-prevention-of-venous-thromboembolism-in-adults-with-cancer\" class=\"medical medical_review\">Risk and prevention of venous thromboembolism in adults with cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=risk-assessment-of-adults-with-chemotherapy-induced-neutropenia\" class=\"medical medical_review\">Risk assessment of adults with chemotherapy-induced neutropenia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=thromboembolism-in-children-with-cancer\" class=\"medical medical_review\">Thromboembolism in children with cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=thrombotic-complications-following-treatment-of-multiple-myeloma-with-immunomodulatory-drugs-thalidomide-lenalidomide-and-pomalidomide\" class=\"medical medical_review\">Thrombotic complications following treatment of multiple myeloma with immunomodulatory drugs (thalidomide, lenalidomide, and pomalidomide)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=toxicity-of-molecularly-targeted-antiangiogenic-agents-cardiovascular-effects\" class=\"medical medical_review\">Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=toxicity-of-molecularly-targeted-antiangiogenic-agents-non-cardiovascular-effects\" class=\"medical medical_review\">Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-neutropenic-fever-syndromes-in-adult-cancer-patients-at-low-risk-for-complications\" class=\"medical medical_review\">Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-neutropenic-fever-syndromes-in-adults-with-hematologic-malignancies-and-hematopoietic-cell-transplant-recipients-high-risk-patients\" class=\"medical medical_review\">Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-venous-thromboembolism-in-patients-with-malignancy\" class=\"medical medical_review\">Treatment of venous thromboembolism in patients with malignancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-granulocyte-colony-stimulating-factors-in-adult-patients-with-chemotherapy-induced-neutropenia-and-conditions-other-than-acute-leukemia-myelodysplastic-syndrome-and-hematopoietic-cell-transplantation\" class=\"medical medical_review\">Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation</a></li></ul></div></div>","javascript":null}